Patent · US Active

Modified DNase and uses thereof

US11814657B2 · kind B2 · utility

0Cited by

6References

19Claims

0Family size

Assignee

Protalix Ltd. · IL

Inventors

Lilach CHEN ZELTSBURG · Nahariah, IL
Ilya Ruderfer · Carmiel, IL
Avidor Shulman · Rakefet, IL
Liat Fux · Kiryat Motzkin, IL
Yulia Ugortsev · Nesher, IL
Hagit Neta · Haifa, IL
Sivan Gelley · Kfar Sava, IL
Elad Lavee Laviad · Even Yehuda, IL
Yoseph Shaaltiel · Beit Hillel, IL

Key dates

Filing date	Dec 20, 2021
Grant date	Nov 14, 2023
Priority date	—
Expiry date	Dec 20, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Modified DNase I protein in which one or more amino acids of a DNase I protein are modified non-cellularly, are provided. The modified DNase I protein exhibits a DNA hydrolytic activity in the presence of actin and an improved DNA hydrolytic activity compared to a homologous non-modified DNase I protein. Processes of preparing the modified DNase I protein and uses thereof in, for example, reducing a DNA content in sputum and/or in treating a disease or condition associated with excess extracellular DNA in a fluid, secretion or tissue of a subject, are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.